Iosune Baraibar

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer